Peer-reviewed veterinary case report
Two dogs with skin lymphoma improved after isotretinoin
By Lee, Ga-Won et al.·Published in BMC veterinary research·2018·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical response to isotretinoin and interferon-α of two dogs with cutaneous epitheliotropic T-cell lymphoma: a case report.
- Species:
- dog
Plain-English summary
A Shih Tzu and a Miniature Pinscher were brought in with multiple nodular skin lesions, which were diagnosed as cutaneous epitheliotropic T-cell lymphoma (CETL), a type of skin cancer. Both dogs were treated with a combination of isotretinoin, a medication often used for severe skin conditions, and interferon-α, an immune-boosting treatment. They showed significant improvement, with some lesions completely disappearing and others reducing in size. After starting treatment, both dogs remained stable and free of new symptoms for over 264 days, and follow-ups showed no signs of the disease returning for up to 27 months.
People also search for: dog skin cancer treatment · Shih Tzu skin lesions · Miniature Pinscher lymphoma therapy
Abstract
BACKGROUND: There is no specific therapy for cutaneous epitheliotropic T-cell lymphoma (CETL). The administration of retinoids in conjunction with interferon-α (IFN-α) in CETL has not been reported in dogs. CASE PRESENTATION: Two dogs (Shih tzu and Miniature pinscher) presented with multiple nodular skin lesions. Histopathological examination revealed diffuse infiltrations of lymphocytes in the epidermis and dermis, with a CD3-positive immunophenotypic profile. Based on the clinical and histopathological examination, CETL was diagnosed. Both dogs were treated with isotretinoin in combination with IFN-α and showed clinical improvement with complete or partial remission. The disease in these dogs was well-controlled for more than 264 days of overall median survival time without any additional clinical signs after initiation of the treatment. In both the cases, the dogs were followed up for 27 months, and 10 months without any evidence of recurrence or metastasis, respectively. CONCLUSIONS: We describe the clinical efficacy of isotretinoin combined with IFN-α in 2 dogs with CETL. Long-term management with isotretinoin combined with IFN-α was effective in treating CETL in these cases.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30514314/